Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Open access
Rivellese, Felice, Surace, Anna E. A., Goldmann, Katriona, Sciacca, Elisabetta, Çubuk, Cankut, Giorli, Giovanni, John, Christopher R., Nerviani, Alessandra, Fossati-Jimack, Liliane, Thorborn, Georgina, Ahmed, Manzoor, Prediletto, Edoardo, Church, Sarah E., Hudson, Briana M., Warren, Sarah E., McKeigue, Paul M., Humby, Frances, Bombardieri, Michele, Barnes, Michael R., Lewis, Myles J., Pitzalis, Costantino, the R4RA collaborative group, Rivellese, Felice, Giorli, Giovanni, Nerviani, Alessandra, Fossati-Jimack, Liliane, Thorborn, Georgina, Humby, Frances, Bombardieri, Michele, Lewis, Myles J., Durez, Patrick, Buch, Maya H., Rizvi, Hasan, Mahto, Arti, Montecucco, Carlomaurizio, Lauwerys, Bernard, Ng, Nora, Ho, Pauline, Romão, Vasco C., da Fonseca, João Eurico Cabral, Verschueren, Patrick, Kelly, Stephen, Sainaghi, Pier Paolo, Gendi, Nagui, Dasgupta, Bhaskar, Cauli, Alberto, Reynolds, Piero, Cañete, Juan D., Ramirez, Julio, Celis, Raquel, Moots, Robert, Taylor, Peter C., Edwards, Chris J., Isaacs, John, Sasieni, Peter, Choy, Ernest, Thompson, Charlotte, Bugatti, Serena, Bellan, Mattia, Congia, Mattia, Holroyd, Christopher, Pratt, Arthur, White, Laura, Warren, Louise, Peel, Joanna, Hands, Rebecca, Hadfield, Gaye, Pitzalis, Costantino·2022·Nature Medicine

Abstract

Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5–20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC) = 0.74), tocilizumab (AUC = 0.68) and, notably, multidrug resistance (AUC = 0.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment–response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01789-0

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 294

Metadata

Authors
Rivellese, F., Surace, A. E. A., Goldmann, K., Sciacca, E., Çubuk, C., Giorli, G., John, C. R., Nerviani, A., Fossati-Jimack, L., Thorborn, G., Ahmed, M., Prediletto, E., Church, S. E., Hudson, B. M., Warren, S. E., McKeigue, P. M., Humby, F., Bombardieri, M., Barnes, M. R., Lewis, M. J., Pitzalis, C., the R4RA collaborative group, Rivellese, F., Giorli, G., Nerviani, A., Fossati-Jimack, L., Thorborn, G., Humby, F., Bombardieri, M., Lewis, M. J., Durez, P., Buch, M. H., Rizvi, H., Mahto, A., Montecucco, C., Lauwerys, B., Ng, N., Ho, P., Romão, V. C., da Fonseca, J. E. C., Verschueren, P., Kelly, S., Sainaghi, P. P., Gendi, N., Dasgupta, B., Cauli, A., Reynolds, P., Cañete, J. D., Ramirez, J., Celis, R., Moots, R., Taylor, P. C., Edwards, C. J., Isaacs, J., Sasieni, P., Choy, E., Thompson, C., Bugatti, S., Bellan, M., Congia, M., Holroyd, C., Pratt, A., White, L., Warren, L., Peel, J., Hands, R., Hadfield, G., & Pitzalis, C.
Venue
Nature Medicine
Published
2022-05-19
Volume
28
Issue
6
Pages
1256-1268
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4280528160
Cited by
294
References
51
FWCI
33.38
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. https://app.cochat.ai/papers/10.1038/s41591-022-01789-0
The paper
Rivellese, F., Surace, A. E. A., Goldmann, K., Sciacca, E., Çubuk, C., Giorli, G., John, C. R., Nerviani, A., Fossati-Jimack, L., Thorborn, G., Ahmed, M., Prediletto, E., Church, S. E., Hudson, B. M., Warren, S. E., McKeigue, P. M., Humby, F., Bombardieri, M., Barnes, M. R., . . . Pitzalis, C. (2022). Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01789-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.